Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Kane Biotech ( (TSE:KNE) ) is now available.
Kane Biotech has received approval from the University of Miami Health System’s Internal Review Board to commence a clinical study of its DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris. This trial, set to begin mid-year at the University of Miami Miller School of Medicine, marks a significant milestone for Kane Biotech as it continues to advance its mission of providing innovative dermatological solutions, potentially impacting millions of individuals suffering from acne.
More about Kane Biotech
Kane Biotech Inc. is a biotechnology company focused on the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company holds a portfolio of biotechnologies, intellectual property, and products, including DispersinB®, coactiv+™, DermaKB™, and others.
YTD Price Performance: -9.09%
Average Trading Volume: 69,421
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$13.06M
Find detailed analytics on KNE stock on TipRanks’ Stock Analysis page.